To date, dulaglutide, semaglutide, and tirzepatide have been the three predominant GLP-1 therapeutics employed in the treatment of T2DM, and their applications have been broadened to include weight management
also demonstrated that exenatide, a GLP-1 receptor agonist (RA), may suppress the expression of MMPs induced by TNF- by inhibiting the phosphorylation of components within the AKT signaling pathway 71
Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is essential to maintaining glycaemic safety which is one reason why retatrutide must only be used under close medical supervision
Any decision involving injectable peptides should be discussed with a licensed medical professional who can assess individual risk factors
About Fybogel (ispaghula husk)
For guidance on what to expect from week 1 to week 12, read our expert guide